GHENT, BELGIUM--(Marketwire - March 26, 2013) - Ablynx (EURONEXT BRUSSELS: ABLX) today announced that its 2013 Annual and Extraordinary General meeting (AGM) will be held on Thursday, 25 April 2013 at 11:00h CET at its headquarters at Technologiepark 21, 9052 Ghent.
The convocation and proxy statement, agenda, and annual accounts 2012 will be directly and permanently available on the Company's website at http://www.ablynx.com/en/investors/shareholder-information/shareholders-meeting/ from 26 March 2013.
The most important resolutions included in the agenda relate to the annual accounts 2012, the renewal of the authorised capital and the composition of the Board of Directors including the resignation of two non-executive Directors: Dr Roger Perlmutter who, to avoid conflicts of interest, is resigning from the Ablynx Board following his recent appointment at Merck & Co. as Executive Vice President and President of Merck Research Laboratories, and Geert Cauwenbergh who after five years will retire from the Ablynx Board.
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and five Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck Serono, Novartis and Merck & Co. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
press release in pdf: http://hugin.info/137912/R/1688051/553673.pdf